Voltaren Gel - Revisions to the Hepatic Effects Section of the Prescribing Information

Voltaren Gel - Revisions to the Hepatic Effects Section of the
Prescribing Information
December 4, 2009
Audience: Rheumatological healthcare professionals, pharmacists.

Endo, Novartis and FDA notified healthcare professionals of revisions
to the Hepatic Effects section of the prescribing information to add
new warnings and precautions about the potential for elevation in
liver function tests during treatment with all products containing
diclofenac sodium. In postmarketing reports, cases of drug-induced
hepatotoxicity have been reported in the first month but can occur at
any time during treatment...

--
esgdivisionmedica.4t.com